RxDoctor Payments Data

Katie Bonar

Family Medicine · Decatur, ALNPI 1083254320

Payments from drug & device makers

$1,427in general payments, 2019–2025

Across 85 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$425
  • AstraZeneca$216
  • Lilly USA, LLC$195
  • AbbVie$147
  • Xeris Pharmaceuticals, Inc.$108
  • GSK$102
  • plus $234 from 9 others

What the payments were for

  • Food & beverage$1,427100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,427 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$46,525
Medicare patients
191
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$125,773
MounjaroTirzepatide108$116,693
FarxigaDapagliflozin Propanediol73$75,324
EliquisApixaban80$72,328
JardianceEmpagliflozin57$50,894
InvokanaCanagliflozin12$24,785
JanuviaSitagliptin Phosphate33$22,774
LinzessLinaclotide21$18,986
TrulicityDulaglutide11$17,814
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,370
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$15,582
MyrbetriqMirabegron22$10,237
Spiriva HandihalerTiotropium Bromide11$7,233
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,415
Breo ElliptaFluticasone/Vilanterol13$6,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$195$134,507119 claims
Novo NordiskOzempic$425$125,773122 claims
AstraZenecaFarxiga, Breztri Aerosphere$216$90,90696 claims
PfizerEliquis$23$72,32880 claims
GSKTrelegy Ellipta, Breo Ellipta$102$22,40231 claims
AbbVieLinzess$147$18,98621 claims
Astellas Pharma US IncMyrbetriq$20$10,23722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →